Cases occupied with a lower risk lesion are expected to continue appointments with physicians for up to 3 years post-surgery. A higher risk lesion is encouraged to consistently consult with physicians during a 7-year period after treatment. Remission events require immediate attention and appropriate procedures such as enucleation or curettage. In more damaging cases of remission, tissue resection, and marsupialization may have to be performed. Epidemiology
The clinical presentation of the GOC is very low in the population as noted by the 0.12 to 0.13% occurrence rate, extrapolated from a sample size of the 181 individuals. The GOC mainly affects older individuals in the population, especially those that are in their 40 to 60s. However, the GOC can affect younger individuals i.e. 11, and more older individuals i.e. 82 in the population. The age distribution starts at a much lower number for people living in Asia and Africa. Those in their first 10 years of life have not been diagnosed with the GOC. The GOC does present a tendency to proliferate in more males than females. There is no definitive conclusion towards the relevance of gender and its influence on the rate of incidence. References
Bibliography
AbdullGaffar, Badr; Koilelat, Mohamed (May 2017). "Glandular Odontogenic Cyst: The Value of Intraepithelial Hemosiderin". International Journal of Surgical Pathology. 25 (3): 250–252. doi:10.1177/1066896916672333. PMID 27829208. S2CID 46588216. Akkaş, İsmail; Toptaş, Orçun; Özan, Fatih; Yılmaz, Fahri (1 March 2015). "Bilateral Glandular Odontogenic Cyst of Mandible: A Rare Occurrence". Journal of Maxillofacial and Oral Surgery. 14 (1): 443–447. doi:10.1007/s12663-014-0668-y. PMC 4379287. PMID 25848155.
It is associated with elevated neurotensin levels.Diagnosis is normally made by imaging (ultrasound, CT or MRI) and biopsy

Treatment
In FHCC, plasma neurotensin and serum vitamin B12 binding globulin are commonly increased and are useful in monitoring the disease and detecting recurrence.FHCC can often be surgically removed. Liver resection is the optimal treatment and may need to be performed more than once, since this disease has a very high recurrence rate. Due to such recurrence, periodic follow-up medical imaging (CT or MRI) is necessary.As the tumor is quite rare, there is no standard chemotherapy regimen. Radiotherapy has been used but data is limited concerning its use. The survival rate for fibrolamellar HCC largely depends on whether (and to what degree) the cancer has metastasized, i.e. spread to the lymph nodes or other organs. Distant spread (metastases), significantly reduces the median survival rate. Five-year survival rates vary between 40–90%. Epidemiology
FHCC accounts for 1–10% of primary liver cancers. It typically has a young age at presentation (20–40 years: mean age ~27 years) when compared to conventional HCC. Unlike the more common HCC, patients most often do not have coexistent liver disease such as cirrhosis. History
This disease was first described by Hugh Edmondson in a 14-year-old female with no underlying liver disease. The name fibrolamellar hepatocellular carcinoma was coined by Craig et al. in 1980. It was not recognised as a distinct form of cancer by the WHO until 2010. Additional images
References


== External links ==